ArriVent BioPharma, Inc. (AVBP)
| Market Cap | 775.61M +2.8% |
| Revenue (ttm) | n/a |
| Net Income | -164.21M |
| EPS | -3.70 |
| Shares Out | 49.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 989,991 |
| Open | 15.67 |
| Previous Close | 15.40 |
| Day's Range | 15.20 - 15.89 |
| 52-Week Range | 11.36 - 35.83 |
| Beta | 1.35 |
| Analysts | Strong Buy |
| Price Target | 25.80 (+64.02%) |
| Est. Earnings | Nov 9, 2026 |
About AVBP
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AVBP stock is "Strong Buy." The 12-month stock price target is $25.8, which is an increase of 64.02% from the latest price.
News
ArriVent Biopharma price target raised to $30 from $18 at Guggenheim
Guggenheim raised the firm’s price target on ArriVent Biopharma (AVBP) to $30 from $18 and keeps a Buy rating on the shares following presentation of first Phase 1 data on…
ArriVent Biopharma price target raised to $21 from $18 at Truist
Truist analyst Supawat Thongthip raised the firm’s price target on ArriVent Biopharma (AVBP) to $21 from $18 and keeps a Buy rating on the shares. The firm views today’s 27%…
ArriVent Biopharma price target raised to $25 from $18 at Oppenheimer
Oppenheimer raised the firm’s price target on ArriVent Biopharma (AVBP) to $25 from $18 and keeps an Outperform rating on the shares.
ArriVent Biopharma announces initial Phase 1 results for ARR-217
ArriVent BioPharma (AVBP) announced initial Phase 1 results for ARR-217, a cadherin-17-targeting antibody-drug conjugate, ADC, developed in partnership with Lepu Biopharma, in patients with gastrointe...
ArriVent BioPharma Transcript: Study update
ARR-217 showed a 44.8% ORR and 93.1% DCR at 6 mg/kg in heavily pretreated metastatic CRC, with mostly low-grade toxicity and 2% Grade 3 diarrhea. Phase Ib monotherapy and combination studies continue; phase III initiation is targeted by end-2027.
ArriVent BioPharma Press release: Study update
ArriVent BioPharma issued a press release on October 26, 2026, disclosing material business information to investors.
ArriVent BioPharma Slides: Study update
ArriVent BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
ArriVent cancer data support ‘best-in-class’ potential, says Clear Street
Clear Street analyst Kaveri Pohlman says ArriVent Biopharma’s (AVBP) initial Phase 1 data for ARR-217 in late-line colorectal cancer met its bull-case scenario” and support the potential for its diffe...
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innov...
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innov...
ArriVent Biopharma price target lowered to $29 from $45 at B. Riley
B. Riley lowered the firm’s price target on ArriVent Biopharma (AVBP) to $29 from $45 and keeps a Buy rating on the shares. Keymed’s CM518D1 showed a 33.3% overall response…
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
NEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innov...
ArriVent Biopharma doses first patient in ARR-002 trial
ArriVent BioPharma (AVBP) announced that it dosed its first patient in the Phase 1 trial in the U.S. with ARR-002, a MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate, or ADC, for ovarian…
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innov...
ArriVent Biopharma price target lowered to $27 from $47 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns lowered the firm’s price target on ArriVent Biopharma (AVBP) to $27 from $47 and keeps a Buy rating on the shares following the FURVENT trial…
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $AVBP--AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law.
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into pote...
ArriVent Biopharma price target lowered to $29 from $42 at BTIG
BTIG analyst Jeet Mukherjee lowered the firm’s price target on ArriVent Biopharma (AVBP) to $29 from $42 and keeps a Buy rating on the shares after the FURVENT Phase 3…
ArriVent Biopharma price target lowered to $18 from $45 at Guggenheim
Guggenheim lowered the firm’s price target on ArriVent Biopharma (AVBP) to $18 from $45 and keeps a Buy rating on the shares after the FURVENT Phase 3 trial evaluating firmonertinib…
ArriVent Biopharma price target lowered to $20 from $40 at Citi
Citi lowered the firm’s price target on ArriVent Biopharma (AVBP) to $20 from $40 and keeps a Buy rating on the shares. The firm removed firmonertinib’ in frontline exon 20…
ArriVent Biopharma price target lowered to $22 from $47 at Clear Street
Clear Street lowered the firm’s price target on ArriVent Biopharma (AVBP) to $22 from $47 and keeps a Buy rating on the shares. Firmonertinib’s Phase 3 FURVENT miss was primarily…
ArriVent Biopharma price target lowered to $22 from $45 at Jones
Jones lowered the firm’s price target on ArriVent Biopharma (AVBP) to $22 from $45 and keeps a Buy rating on the shares. The company’s Phase III failed to meet the…
ArriVent Biopharma price target lowered to $18 from $45 at Truist
Truist lowered the firm’s price target on ArriVent Biopharma (AVBP) to $18 from $45 and keeps a Buy rating on the shares. The company disclosed this morning that FURVENT missed…
ArriVent Biopharma price target lowered to $18 from $45 at Jefferies
Jefferies lowered the firm’s price target on ArriVent Biopharma (AVBP) to $18 from $45 and keeps a Buy rating on the shares after the company announced that the FURVENT Phase…
ArriVent says Phase 3 firmonertinib trial did not meet endpoint
ArriVent BioPharma (AVBP) announced that the FURVENT Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cel...